This does make the Celltex case in Texas come back to light again as a few weeks ago it was all over the news. These were all non substantiated stem cell treatments to where fat cells were taken, shipped to Korea and then returned. Perhaps the FDA has another upcoming inspection? As this article points out though lawyers know a good lawsuit when they see one. Any MD who is participating in non substantiated stem cell procedures today is walking on thin ice. We do hear so many claims about stem cells and sometimes folks can’t tell the difference especially when any of their other treatments have not worked prior.
The treatments all took place in China or Tijuana and at the Mexico location, 5 of the patients developed infections after their injections, not good. RNL Bio is the parent company of Human Biostar. Back to the Texas case, who was Celltex doing business with, RNL Bio. BD
In what could be a landmark case, six patients in California are suing one of the world’s largest stem-cell companies for allegedly misleading them about the effectiveness of its stem-cell treatments.
The six patients all live in Los Angeles or Orange County and share the last name Lee. Some of them are related, according to their lawyer, the unrelated Sang I Lee. They are suing Human Biostar based in Sugar Land, Texas; Jin Han Hong, the company’s chief operating officer; and Jeong Chan Ra, a Korean citizen and chairman of the board of Seoul-based RNL Bio, the parent company of Human Biostar.
The six patients claim they were sold the procedures by Hong when he was president RNL Life Science, another subsidiary of RNL Bio, based in Los Angeles. The procedure consists of taking fat from a patient, removing stem cells from the sample, processing and expanding them in RNL’s Seoul laboratory, and then sending them to one of RNL’s clinics to inject them into patients to treat a variety of diseases.
The case could bring closer scrutiny to stem-cell treatments throughout the United States. Until now, clinics advertising or selling unproven and unapproved stem cell treatments to patients had to worry only about the FDA, which monitors the clinical use of stem cells to ensure safety and efficacy — but moves slowly and bureaucratically.